Phagenesis Ltd, a Manchester Science Park-based provider of technology designed to treat patients who are dysphagic following a stroke, has been awarded c. £1m from the Wellcome Trust.
Led by CEO Daniel Green, Phagenesis has developed a clinically-proven device to treat dysphagia in stroke patients in the first few weeks while they are hospitalised. With the support of the Wellcome Trust, the company is now developing and testing a new version of its device to treat patients suffering from long-term dysphagia.
FinSMEs
22/05/2012
Related News
04/10/2011: Phagenesis Closes €7M Series B Funding Round
11/09/2010: Phagenesis Receives £2M Investment